Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)

BACKGROUND: Risk assessment on the molecular level is important in predictive pathology to determine the risk of metastatic disease for ERpos, HER2neg breast cancer. The gene expression test EndoPredict (EP) was trained and validated for prediction of a 10-year risk of distant recurrence to support...

Descripción completa

Detalles Bibliográficos
Autores principales: Jank, Paul, Lindner, Judith Lea, Lehmann, Annika, Pfitzner, Berit Maria, Blohmer, Jens-Uwe, Horst, David, Kronenwett, Ralf, Denkert, Carsten, Schmitt, Wolfgang Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763835/
https://www.ncbi.nlm.nih.gov/pubmed/34783927
http://dx.doi.org/10.1007/s10549-021-06415-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763835/
https://www.ncbi.nlm.nih.gov/pubmed/34783927
http://dx.doi.org/10.1007/s10549-021-06415-0

Ejemplares similares